Bayer (FRA:BAYN) received a €89.00 ($103.49) target price from equities research analysts at Sanford C. Bernstein in a report released on Monday, Borsen Zeitung reports. The firm presently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s price objective points to a potential upside of 58.73% from the company’s current price.
Several other research firms also recently commented on BAYN. Goldman Sachs Group set a €77.00 ($89.53) price objective on Bayer and gave the company a “buy” rating in a research note on Monday, April 29th. DZ Bank reaffirmed a “neutral” rating on shares of Bayer in a research note on Tuesday, April 2nd. Deutsche Bank set a €70.00 ($81.40) price objective on Bayer and gave the company a “neutral” rating in a research note on Thursday, April 25th. Barclays set a €85.00 ($98.84) price objective on Bayer and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on Bayer and gave the company a “neutral” rating in a research note on Wednesday, March 20th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of €81.67 ($94.97).
BAYN opened at €56.07 ($65.20) on Monday. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: What is range trading?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.